You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Dalbavancin hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for dalbavancin hydrochloride and what is the scope of freedom to operate?

Dalbavancin hydrochloride is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Dalbavancin hydrochloride has fifty-eight patent family members in twenty countries.

One supplier is listed for this compound.

Summary for dalbavancin hydrochloride
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dalbavancin hydrochloride
Generic Entry Date for dalbavancin hydrochloride*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for dalbavancin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 4
APHPPhase 3
Centre Hospitalier Annecy GenevoisPhase 3

See all dalbavancin hydrochloride clinical trials

Pharmacology for dalbavancin hydrochloride

US Patents and Regulatory Information for dalbavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for dalbavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for dalbavancin hydrochloride

Country Patent Number Title Estimated Expiration
Russian Federation 2008142899 КОМПОЗИЦИИ ДАЛБАВАНЦИНА ДЛЯ ЛЕЧЕНИЯ БАКТЕРИАЛЬНЫХ ИНФЕКЦИЙ ⤷  Try a Trial
Japan 2011157381 METHOD OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTION ⤷  Try a Trial
Hong Kong 1083684 Methods of administering dalbavancin for treatmentof bacterial infections ⤷  Try a Trial
South Korea 20070015179 DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS ⤷  Try a Trial
Brazil PI0510269 composições de dalbavancina para o tratamento de infecções bacterianas ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.